← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Ultragenyx Pharmaceutical RARE $1.47B	311	+13	+4%	$3.55B
27	27 Adaptive Biotechnologies ADPT $4.09B	300	+2	+0.7%	$3.34B
28	28 Beam Therapeutics BEAM $2.44B	277	+24	+9%	$3.75B
29	29 ARK Genomic Revolution ETF ARKG $2.05B	274	+54	+25%	$1.48B
30	30 uniQure QURE $1.45B	254	+40	+19%	$3.02B
31	31 Azenta AZTA $1.63B	249	-11	-4%	$1.28B
32	32 Caris Life Sciences CAI $8.55B	247	+45	+22%	$2.75B
33	33 Wave Life Sciences WVE $609M	239	+7	+3%	$1.06B
34	34 CareDx CDNA $3.35B	227	+36	+19%	$1.5B
35	35 Pacific Biosciences PACB $619M	223	-8	-3%	$321M
36	36 GeneDx Holdings WGS $2.05B	223	-18	-7%	$2.17B
37	37 Legend Biotech LEGN $3.7B	219	+29	+15%	$2.98B
38	38 DELISTED BioLife Solutions BLFS	216	+29	+16%	$1.4B
39	39 Editas Medicine EDIT $349M	215	+7	+3%	$386M
40	40 Sana Biotechnology SANA $698M	211	+8	+4%	$644M
41	41 Precigen PGEN $2.64B	210	+4	+2%	$799M
42	42 Allogene Therapeutics ALLO $449M	209	0	0%	$652M
43	43 Taysha Gene Therapies TSHA $1.14B	208	+17	+9%	$2.06B
44	44 Stoke Therapeutics STOK $1.5B	197	-1	-0.5%	$2.49B
45	45 Myriad Genetics MYGN $397M	196	-7	-3%	$508M
46	46 Prime Medicine PRME $568M	187	-5	-3%	$393M
47	47 Ginkgo Bioworks DNA $776M	183	+8	+5%	$359M
48	48 Rocket Pharmaceuticals RCKT $243M	180	-19	-10%	$341M
49	49 Maravai LifeSciences MRVI $976M	177	+19	+12%	$876M
50	50 Arbutus Biopharma ABUS $830M	176	+9	+5%	$675M